Employees: 192
Size Genfit (GNFT.PA) is a France Health Care company (Biotechnology) with a market value of $571M, the 169th largest of 206 France companies the cockpit tracks. Shares closed at €10.42 on 18 Nov 2026.
Performance Over six months the shares gained 22.2%, against -20.4% for the median peer and -2.1% for the France market (cap-weighted) — 3rd highest of 19 in its peer set.
Growth Revenue grew 27.7% over the last twelve months (peer median +7.7%); the operating margin is -130.4% (peer median -10.7%).
Valuation It trades at 431.5× forward earnings against a peer median of 21.5× (most expensive of 8).
Price implies For today's price to make sense, revenue must grow about 40% a year for seven years (Req g). Recent delivered growth is +143%, so the hurdle is -104 pp: the price already allows for a slowdown.
Next results Next results expected around 8 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | €53.0M | €65.4M | €67.0M | €28.6M | €20.2M |
| Revenue growth | — | -2% | +135% | +41% | — |
| Gross profit | €1.01M | €14.6M | €65.3M | n/a | n/a |
| EBITDA | -€17.1M | -€8.04M | €1.39M | -€34.9M | -€31.2M |
| Net income | -€102M | -€86.0M | €1.51M | -€28.9M | -€23.7M |
| Free cash flow | €7.50M | -€26.7M | €14.2M | -€56.3M | -€74.7M |
| Capital expenditure | €914,000 | €3.42M | €979,000 | €2.49M | €0 |
| Total debt | n/a | €151M | €62.1M | €70.2M | €75.3M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | GNFT.PA | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +15.8% | -14.3% | 4th highest of 21 |
| 6-month return | +22.2% | -20.4% | 3rd highest of 19 |
| Distance from 52-week high | -32.7% | -50.5% | 4th highest of 21 |
| Revenue growth (TTM) | +27.7% | +7.7% | 6th highest of 17 |
| Operating margin | -130.4% | -10.7% | 7th lowest of 17 |
| Forward P/E | 431.5× | 21.5× | most expensive of 8 |
| Growth the price implies (Req g, 7 yrs) | 39.8% | 14.3% | most demanding of 4 |
| Growth delivered (Del g) | +143.5% | +15.4% | highest of 4 |
| Hurdle (Req g minus delivered) | -103.6 pp | -1.1 pp | least demanding of 4 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Genfit GNFT.PA | France | $571M | +22% | +28% | -130% | 431.5× | 39.8% | +143.5% |
| Ascletis Pharma 1672.HK | Hong Kong | $571M | -72% | -59% | -71,976% | n/a | n/a | n/a |
| 4D Molecular Therapeutics FDMT | United States | $578M | +23% | +79,952% | -226% | n/a | n/a | n/a |
| Boji Medical Technology 300404.SZ | China | $561M | -6% | +32% | 4% | 69.3× | 31.9% | +27.2% |
| Sana Biotechnology SANA | United States | $554M | -41% | n/a | n/a | n/a | n/a | n/a |
| Hvsen Biotechnology 300871.SZ | China | $553M | -22% | +2% | 17% | 11.7× | n/a | n/a |
| Alebund Pharmaceuticals (Jiangsu) 9637.HK | Hong Kong | $595M | n/a | +674% | -495% | n/a | n/a | n/a |
| Wave Life Sciences WVE | United States | $546M | -55% | -35% | -321% | n/a | n/a | n/a |
| Climb Bio CLYM | United States | $546M | -12% | n/a | n/a | n/a | n/a | n/a |
| Frontage 1521.HK | Hong Kong | $542M | +113% | +10% | 8% | 24.6× | 14.3% | +15.4% |
| Anhui Huaheng Biotechnology 688639.SS | China | $605M | -45% | +7% | 3% | 22.3× | n/a | n/a |
| Surrozen SRZN | United States | $605M | +17% | +192% | -485% | n/a | n/a | n/a |
| Design Therapeutics DSGN | United States | $606M | -15% | n/a | n/a | n/a | n/a | n/a |
| Getein Biotech 603387.SS | China | $625M | -13% | +8% | 21% | n/a | -8.9% | -1.3% |
| Beijing Bohui Innovation Biotechnology 300318.SZ | China | $518M | -20% | -1% | -13% | n/a | n/a | n/a |
| Janux Therapeutics JANX | United States | $631M | -28% | +133% | -599% | n/a | n/a | n/a |
| Shenzhen Weiguang Biological Products 002880.SZ | China | $633M | -27% | 0% | 18% | 19.2× | n/a | n/a |
| LongBio Pharma (Suzhou) 1779.HK | Hong Kong | $510M | n/a | n/a | n/a | n/a | n/a | n/a |
| Geron GERN | United States | $638M | -21% | +19% | -8% | 17.4× | n/a | n/a |
| Valneva VLA.PA | France | $508M | -6% | -27% | -87% | n/a | n/a | n/a |
| Beijing Scitop Bio-Tech 300858.SZ | China | $501M | -28% | +4% | 8% | 21.5× | n/a | n/a |